A Phase I Trial of Af-001 in Patients With Differentiated Thyroid Cancer

This trial consists of 2 parts, i.e., Part Ia and Ib. The Part Ia is to evaluate the safety and tolerability of a single intravenous dose of af-001 in patients with radically unresectable, recurrent, metastatic differentiated thyroid cancer (papillary carcinoma, follicular carcinoma) refractory to or intolerant of standard-of-care therapy, who have received total thyroidectomy, and to determine the MTD (Maximum tolerated dose). Part Ib is to evaluate the efficacy and safety of af-001 mutiple doses to patients with radically unresectable, recurrent, metastatic differentiated thyroid cancer (pa

Trial Details

NCT ID
NCT07287748
Phase
PHASE1
Sponsor
Alpha Fusion Inc.
Status
RECRUITING
Cancer Type
Papillary Thyroid Cancer
Interventions
  • [211At]NaAt
Locations (sample)
  • Kashiwa, Japan|35.86224,139.97732

Key Eligibility Criteria

  • \<Ia part\>
  • Patients with differentiated thyroid cancer (papillary carcinoma, follicular carcinoma) after total thyroidectomy.
  • Patients with radically unresectable, recurrent, metastatic disease who are judged by the principal investigator or sub-investigator (hereinafter, …
  • \<Ib part\>

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Papillary Thyroid Cancer Trials on Trialify →